资讯

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track ...
Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...
Investing1 个月
Vanda Pharmaceuticals develops ASO therapy for rare disease
(NASDAQ: NASDAQ:VNDA), a biopharmaceutical company with impressive gross profit margins of 94.3% and a market capitalization of $258 million, has recently announced the development of a novel ...
Pharm Exec7 天
FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidate
The FDA has granted Fast Track designation to Biogen’s BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau for the treatment of Alzheimer disease (AD). In a press release ...
Morningstar7 天
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track ...
(Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting ...
Biogen announces U.S. FDA granted Fast Track designation to BIIB080
Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to BIIB080, an investigational ...